Name: Brensocatib
Price: Inquiry

- Overview
  - Rensocatib is a reversible inhibitor of DPP-1, also known as cathepsin C, which is a peptidase involved in the activation of neutrophil, an elastase-like serine protease in lung tissue. Brensocatib is an oral drug used to treat infections of the airways (lungs) that are characterised by a permanent enlargement and presenting symptoms such as, coughing and greater mucus production (bronchiectasis). Alternative names of brensocatib are INS-1007 and AZD7986.
    
    Please contact us at for specific academic pricing.
- Properties
  - Categories
    
    Enzyme Modulators
    
    Alternative Name
    
    AZD 7986; (S)-N-((S)-1-Cyano-2-(4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-1,4-oxazepane-2-carboxamide
    
    CAS Number
    
    1802148-05-5
    
    Molecular Formula
    
    C23H24N4O4
    
    Molecular Weight
    
    420.46 g/mol
    
    Note
    
    There is no hazardous surcharge associated with this product.
    There is no special packaging charge associated with this product.
    
    * For research use only. Not for human or veterinary use
- Reference
  - Chalmers et al (2020). Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis. The new England Journal of Medicine 383:2127-2137.
    Doyle et al (2016). Discovery of Second Generation Reversible Covalent DPP1 Inhibitors Leading to an Oxazepane Amidoacetonitrile Based Clinical Candidate (AZD7986). Journal of Medicinal chemistry 59(20):9457–9472.

MSDS

Documents

Specification

We Also Recommend

Apigenin - 94%

Arbidol hydrochloride

Baricitinib

Boceprevir

$277

Camostat mesylate- Bio-X

Colchicine

$257

Colchicine

$352

Colchicine

$197

Colchicine

$188

Disulfiram

$188